Woman specialist working with advanced equipment

Home About Clinical Research

Clinical Research

Contact Research Team Study Participants

Cincinnati Eye Institute is home to one of the largest and most prestigious private-sector clinical research departments in ophthalmology in the United States. The eye doctors and research staff at CEI have been conducting clinical research for more than 35 years and have participated in over 300 research studies. Our goal is to pave the way for tomorrow’s eye care and bring it to our patients today.

Contact Research Team Study Participants

Current Clinical Studies

Glaukos (GLK-411-01)

Glaucoma Surgical Device
A Prospective, Multicenter Study of the Preserflo Microshunt in Subjects with Primary Open-Angle Glaucoma Who Have Failed Previous Medical and Surgical Treatment.

Physician: Anup Khatana, MD
Location: 1945 CEI Drive, Cincinnati, OH 45242
Coordinator: Lee Stokes, (513) 569-3213

Spyglass (SGP-005)

Glaucoma Surgical Device
A Prospective, Multicenter, Randomized, Masked, Controlled Study to Evaluate the Safety and Efficacy of the Bimatoprost Implant System used in combination with the SpyGlass IOL

Physician: Anup Khatana, MD
Location: 1945 CEI Drive, Cincinnati, OH 45242
Coordinator: Meagana Wilkins, (513) 569-3285

Abbvie (M22-087)

Glaucoma Surgical Device
A Prospective, Multicenter Clinical Study to Evaluate the Safety and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Subjects with Glaucoma

Physician: Daniel Hammer, MD
Location: 1945 CEI Drive, Cincinnati, OH 45242
Coordinator: Lee Stokes, (513) 569-3213

Ocusun (GOCS-H101-E06)

Eyedrop study for age related cataract
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Pilot Study to Evaluate the Efficacy and Safety of ZOC2017217 in Subjects with Age-Related Cataract

Physician: Michael Nordlund, MD
Location: 1945 CEI Drive, Cincinnati, OH 45242
Coordinator: Meagana Wilkins, (513) 569-3285

Mass General (ExCrossV)

Surgical corneal transplant
ExCrossV ExVivo Corneal Crosslinking of Donor Corneal Tissue for Vascularized High-Risk Keratoplasty

Physician: Kavitha Sivaraman, MD
Location: 1945 CEI Drive, Cincinnati, OH 45242
Coordinator: Meagana Wilkins, (513) 569-3285

Dompe (ICY-DED-201)

Eyedrop study for dry eye
A 12-Week, Phase 2, Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel Group Study With 2 Weeks of Follow-Up to Evaluate the Efficacy and Safety of DFL24498 0.08% Topical Ophthalmic Solution Versus Vehicle in Participants with Dry Eye Disease

Physician: Edward Meier, MD
Location: 6150 Radio Way, Mason, OH 45040
Coordinator: Tina Winward, (513) 770-4020 ext. 3324

Genentech (ML43000 Belvedere)

Surgical trial for wet AMD using the port delivery system
A Phase IIIb/IV, Multicenter, Visual Assessor Masked Study of the Efficacy and Safety of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration Previously Treated with Intravitreal Agents Other than Ranibizumab.

Physician: Lucas Lindsell, OD, MD
Location: 9997 Carver Road, Cincinnati, OH 45242
Coordinator: Paige Byars, (513) 569-3147

Genentech (GR40549 Iridex)

Surgical trial for wet AMD using the port delivery system
Transscleral Photocoagulation Laser Substudy in association with study GR40549 ranibizumab port delivery system for patients with wet macular degeneration

Physician: Lucas Lindsell, OD, MD
Location: 9997 Carver Road, Cincinnati, OH 45242
Coordinator: Paige Byars, (513) 569-3147

Regeneron (Sienna R33918-AMD-2326)

Subcutaneous Injection for patients with Geographic Atrophy due to Age-related macular degeneration
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination with Cemdisiran or Cemdisiran Alone in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration (AMD)

Physician: Robert Foster, MD
Location: 9997 Carver Road, Cincinnati, OH 45242
Coordinator: Mason Adams, (513) 569-3787

4D Molecular Therapeutics (4Front-2)

Injection trial for wet-AMD
Phase 3 clinical trial in patients with Neovascular (Wet) Age-Related Macular Degeneration (nAMD). The primary objective of the study is to establish the efficacy and safety of 4D-150, an AAV based genetic medicine, administered to a single eye as a single injection in adults with nAMD.

Physician: Robert Sisk, MD
Location: 9997 Carver Road, Cincinnati, OH 45242
Coordinator: Noah Wendt, (513) 569-3479

EyeBio Technologies (MK-8748-002)

Injection trial for wet-AMD
A Randomized, Double-Masked, Multi-Center, 3-Arm Pivotal Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) EYE201/MK-8748 Compared with Intravitreal Aflibercept (2 mg) in Participants with Neovascular Age-Related Macular Degeneration (NVAMD)

Physician: Daniel Miller, MD
Location: 9997 Carver Road, Cincinnati, OH 45242
Coordinator: Novale Manning, (513) 569-3170

Meet Our Clinical Research Team

Megan Kingdon

Director of Clinical Research

EyeCare Partners

Kelye Conrad

Clinical Research Manager, Ohio Region

EyeCare Partners

How Does Clinical Research Help Our Patients?

Thousands of patients with eye problems come to CEI each week to find leading-edge solutions to their eye care needs. In addition to patients from Ohio and Northern Kentucky, we see patients who travel from all over the nation to see our eye care experts. Our participation in clinical research allows us to offer patients the most advanced treatment options possible.

Staying on the Leading Edge of Eye Care Research

Our on-going commitment to physician-controlled eye care research enables us:

To provide patients with new treatment options
To be at the forefront of vision care advances
To create an environment for lifelong learning and advancement
To advance the future of eye health and vision

The doctors at Cincinnati Eye Institute have either authored or reviewed the content on this site.

Clinical Research

Current Clinical Studies

Glaucoma